Hypotension Associated With Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Pediatrics

• Publication date

  2016-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1542/peds.2015-2005PMID 26743817
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bevacizumab: A dose review.

  2015cited by this paper
• Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity.

  2015cited by this paper
• Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.

  2015cited by this paper
• Bevacizumab in elderly patients with metastatic colorectal cancer.

  2014cited by this paper
• Intravitreal bevacizumab monotherapy for retinopathy of prematurity

  2013cited by this paper
• Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials.

  2013cited by this paper
• Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer

  2011cited by this paper
• Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

  2011cited by this paper
• INTRAVITREAL BEVACIZUMAB AS SUPPLEMENTAL TREATMENT OR MONOTHERAPY FOR SEVERE RETINOPATHY OF PREMATURITY

  2011cited by this paper
• Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

  2011cited by this paper
• Identifying systemic safety signals following intravitreal bevacizumab: systematic review of the literature and the Canadian Adverse Drug Reaction Database.

  2010cited by this paper
• Vascular endothelial growth factors and vascular permeability

  2010cited by this paper
• Blood pressure disorders in the neonate: hypotension and hypertension.

  2006cited by this paper
• Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

  2006cited by this paper
• Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity.

  1996cited by this paper

• Study of the Biological Developmental Characteristics of the Eye in Children After Laser Surgery for the Treatment of Retinopathy of Prematurity

  2022cites this paper
• Intravitreal Bevacizumab is Associated with Prolonged Ventilatory Support in Preterm Infants with Bronchopulmonary Dysplasia.

  2022cites this paper
• National guideline for ophthalmological screening of premature infants in Germany (S2k level, AWMF guidelines register no. 024/010, March 2020)

  2022cites this paper
• Evaluation of Infants with Retinopathy of Prematurity Treated with Intravitreal Bevacizumab

  2022cites this paper
• Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors

  2021cites this paper
• Hypertension in neonates treated with intravitreal bevacizumab for retinopathy of prematurity

  2021influential citation
• Augenärztliche Screening-Untersuchung bei Frühgeborenen (S2k-Level, AWMF-Leitlinien-Register-Nr. 024/010, März 2020)

  2021cites this paper
• Aggressive Posterior Retinopathy of Prematurity (APROP): LASER as the Primary Modality of Treatment

  2021cites this paper
• Acute and chronic effects of intravitreal bevacizumab on lung biomarkers of angiogenesis in the rat exposed to neonatal intermittent hypoxia

  2020cites this paper
• Bevacizumab in Retinopathy of Prematurity : Concerns and adverse effects.

  2020cites this paper
• Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity

  2018cites this paper
• Role of cytokines and treatment algorithms in retinopathy of prematurity

  2017cites this paper
• Visual outcome and refractive status in first 3 years of age in preterm infants suffered from laser-treated Type 1 retinopathy of prematurity (ROP): a 6-year retrospective review in a tertiary centre in Hong Kong

  2017cites this paper
• Drugs That Act on the Immune System: Cytokines and Monoclonal Antibodies

  2016cites this paper
• Involvement of Renin-Angiotensin System in Retinopathy of Prematurity - A Possible Target for Therapeutic Intervention

  2016cites this paper